Expert Interview
Discussing the results of the AUGMENT-101 Phase 2 clinical trial of Syndax Pharma's Revumenib in patients with acute leukemia.
Ticker(s): SNDXInstitution: Fred Hutchinson Cancer Center
- Professor, Clinical Research Division, at Fred Hutch & Director of the largest genome and transcriptome sequencing project in pediatric and young adult AML.
- Developed numerous clinical assays that have been implemented in cooperative group trials; Created a robust biorepository of viable cells, plasma and extracted nucleic acids from over 100,000 specimens from 3,000 patients.
- Expert in leukemia biology, peripheral blood stem cell transplantation for children with leukemia, management of post-transplant relapse and targeted therapies for acute myeloid leukemia patients.
On a scale of 1 to 10 how excited are you regarding Revumenib following this data release?
Added By: max_adminCould you describe the current treatment options for relapsed/refractory KMT2A-rearranged AML and discuss the expected prognostic outcomes?
In your estimation, what proportion of leukemia patients have KMT2A rearrangements?
What was your impression of the efficacy reported from the AUGMENT-101 results?
How do the achievement of MRD negative status and the number of patients going to transplant impact your view of the drug's efficacy?
How do the results from the AUGMENT-101 Phase 2 trial compare to expectations based on other targeted agents in AML?
Does the reported duration of CR/CRh from the AUGMENT-101 trial impact your view of revumenib?
What concerns, if any, do you have about managing differentiation syndrome and QTc prolongation as adverse events?
How might your expectations differ for the results from the relapsed/refractory NPM1 mutated AML cohort compared to the KMT2A cohort?
Are there any combination trials or maintenance uses of revumenib that you find particularly interesting or promising?
Based on the presented data, do you believe revumenib has met the standard for approval in KMT2A-rearranged leukemia?
If approved, how excited would you be to use revumenib in your practice?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
